Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07529808 is registered in ClinicalTrials.gov with BigHat Biosciences, Inc. as lead sponsor.

NCT NCT07529808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Lead sponsor
BigHat Biosciences, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 16, 2026
Completion date
December 31, 2028
Enrollment
164 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer, cdh17-positive advanced solid tumors, colorectal (colon or rectal) cancer, gastric (stomach) cancer, gastric adenocarcinoma, gastric cancer, gastroesophageal adenocarcinoma, gastroesophageal cancer (gc), gastroesophageal junction (gej) adenocarcinoma, gastroesophageal junction (gej) cancer, gastrointestinal adenocarcinoma, gastrointestinal cancer metastatic, gastrointestinal cancers, pancreatic cancer